No Data
ANTENGENE-B: 2024 INTERIM REPORT
Thailand Approves Antengene's New Drug Application for Multiple Myeloma Drug
Deqi Pharmaceuticals-B (06996.HK): Applications for the marketing approval of two new drugs for different indications of Xiwio have been approved by the Thai Food and Drug Administration.
Gelonghui September 23rd | Deqi Pharmaceutical-B (06996.HK) announced that the Thai Food and Drug Administration has approved the new drug application (NDA) for Xyvio (selinexor tablets) for two indications: (1) in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy; and (2) in combination with dexamethasone, for the treatment of MM patients who have received at least four prior therapies, including resistance to at least two proteasome inhibitors, two immunomodulators, and one anti-CD38 monoclonal antibody and whose disease has worsened in the last treatment.
Express News | Antengene Corp - Approval of Nda by Thailand Food and Drug Administration for Xpovio for Two Indications
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Deqi Medicine - B (06996) fell by 32.70%, now at 0.660 yuan, hitting a new 52-week low.
As of 11:45, Deqi Pharmaceuticals - B (06996) fell 32.70% from the previous closing price, now at 0.660 yuan, hitting a 52-week low; the volume was 0.021 million shares, with a turnover of 0.0141 million Hong Kong dollars.
No Data
No Data